Mode
Text Size
Log in / Sign up
N/A N=124 Randomized Triple-blind Treatment

Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles

Skin Aging

Enrolled (actual)
124
Serious AEs
0.8%
Results posted
Mar 2019
Primary outcome: Primary: Global Wrinkling - Change From Baseline to Week 12, Averaged Expert Grader Scores — 0.18; 0.30 Units on a scale — p=<0.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Active Mask (Device); Sham Mask (Device)
Age
Adult, Older Adult · 35+ yrs
Sex
Female
Sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Primary completion
Jan 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Global Wrinkling - Change From Baseline to Week 12, Averaged Expert Grader Scores
0.18; 0.30 <0.001 sig
PRIMARY
Global Wrinkling - Change From Baseline to Week 12, Individual Expert Grader Scores - Expert Grader 1
0.20; 0.22 <0.001 sig
PRIMARY
Global Wrinkling - Change From Baseline to Week 12, Individual Expert Grader Scores - Expert Grader 2
-0.03; 0.21 0.627
PRIMARY
Global Wrinkling - Change From Baseline to Week 12, Individual Expert Grader Scores - Expert Grader 3
0.36; 0.47 <0.001 sig
SECONDARY
Global Wrinkling - Change From Baseline to Week 1
0.03; 0.04
SECONDARY
Global Wrinkling - Change From Baseline to Week 4
0.09; 0.09
SECONDARY
Global Wrinkling - Change From Baseline to Week 24
0.24; 0.30
SECONDARY
Fine Lines - Change From Baseline to Week 1
0.01; 0.05
SECONDARY
Fine Lines - Change From Baseline to Week 4
0.08; 0.13
SECONDARY
Fine Lines - Change From Baseline to Week 12
0.23; 0.32
SECONDARY
Fine Lines - Change From Baseline to Week 24
0.28; 0.29
SECONDARY
Periorbital Wrinkles - Change From Baseline to Week 1
0.00; 0.01
SECONDARY
Periorbital Wrinkles - Change From Baseline to Week 4
0.10; 0.10
SECONDARY
Periorbital Wrinkles - Change From Baseline to Week 12
0.15; 0.30
SECONDARY
Periorbital Wrinkles - Change From Baseline to Week 24
0.22; 0.29
SECONDARY
Surface Roughness - Change From Baseline to Week 1
0.35; 0.38
SECONDARY
Surface Roughness - Change From Baseline to Week 4
0.79; 0.76
SECONDARY
Surface Roughness - Change From Baseline to Week 12
0.94; 0.89
SECONDARY
Surface Roughness - Change From Baseline to Week 24
1.12; 0.95
SECONDARY
Uneven Skin Tone - Change From Baseline to Week 1
0.04; 0.06
SECONDARY
Uneven Skin Tone - Change From Baseline to Week 4
0.18; 0.23
SECONDARY
Uneven Skin Tone - Change From Baseline to Week 12
0.36; 0.49
SECONDARY
Uneven Skin Tone - Change From Baseline to Week 24
0.44; 0.52
SECONDARY
Mottled Hyperpigmentation - Change From Baseline to Week 1
-0.01; -0.02
SECONDARY
Mottled Hyperpigmentation - Change From Baseline to Week 4
0.10; 0.15
SECONDARY
Mottled Hyperpigmentation - Change From Baseline to Week 12
0.22; 0.39
SECONDARY
Mottled Hyperpigmentation - Change From Baseline to Week 24
0.25; 0.31
SECONDARY
Sallowness/Yellowing - Change From Baseline to Week 1
-0.01; 0.01
SECONDARY
Sallowness/Yellowing - Change From Baseline to Week 4
0.12; 0.12
SECONDARY
Sallowness/Yellowing - Change From Baseline to Week 12
0.23; 0.33
SECONDARY
Sallowness/Yellowing - Change From Baseline to Week 24
0.29; 0.32
SECONDARY
Lack of Radiance - Change From Baseline to Week 1
0.07; 0.13
SECONDARY
Lack of Radiance - Change From Baseline to Week 4
0.28; 0.37
SECONDARY
Lack of Radiance - Change From Baseline to Week 12
0.41; 0.55
SECONDARY
Lack of Radiance - Change From Baseline to Week 24
0.54; 0.59

Summary

This research study will test how well a light therapy mask works for women with mild to moderate hyperpigmentation (brown spots) and moderate to severe facial wrinkles, as compared to a "sham" or inactive investigational light therapy mask. The study will also test if the light therapy mask causes any irritation. For the first 12 weeks of the study, participants will use the assigned mask, along with a provided cleanser and sunscreen. For the second 12 weeks of the study, participants will use just the cleanser and sunscreen.

Eligibility Criteria

Inclusion Criteria

  • Has mild to moderate brown spots
  • Has moderate to severe facial wrinkling
  • Able to read, write, speak, and understand English
  • In general good health
  • If capable of having a child: must agree to practice a medically acceptable form of birth control.
  • Intends to complete the study and willing to follow all study directions.

Exclusion Criteria

  • Allergies/sensitivity to skincare products or the test product ingredients
  • Has a light or photosensitivity disorder or another medical condition that could increase risk to the subject or confuse the study results.
  • Is taking medication that may cause skin sensitivity to light
  • Has been using a product or medication that the study investigator determines will increase health risk to the subject or confuse the study results
  • Has a facial skin condition (e.g. rosacea, acne, eczema, etc.) that could increase health risk to the subject or confuse the study results.
  • Has skin cancer or a history of skin cancer.
  • Has an immune deficiency disorder, active hepatitis, or an autoimmune disease.
  • Has an uncontrolled metabolic condition (e.g. diabetes, hypertension)
  • Is pregnant, nursing, or planning to become pregnant.
  • Plans to start or change a hormone replacement therapy during the study.
  • Has participated in another study in the past 30 days or plans to during the study.
  • Is an employee or relative of the Study Site, Investigator, or Sponsor.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03312543). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search